Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
Priothera SAS
366 participants
Jun 16, 2022
INTERVENTIONAL
Conditions
Summary
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
S1PR modulator
Locations(108)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05429632